LEADER 03498nam  2200589Ia 450 
001 9910144093303321
005 20180702173038.0
010   $a1-281-84052-1
010   $a9786611840525
010   $a0-470-69740-7
010   $a0-470-69741-5
035   $a(CKB)1000000000551489
035   $a(EBL)366846
035   $a(OCoLC)437234437
035   $a(SSID)ssj0000136162
035   $a(PQKBManifestationID)11150469
035   $a(PQKBTitleCode)TC0000136162
035   $a(PQKBWorkID)10064010
035   $a(PQKB)11282680
035   $a(MiAaPQ)EBC366846
035   $a(EXLCZ)991000000000551489
100   $a20080305d2008      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aDefining optimal immunotherapies for type 1 diabetes$b[electronic resource] /$f[editors: Gregory Bock and Jamie Goode]
210   $aLondon $cNovartis Foundation$d2008
215   $a1 online resource (224 p.)
225 1 $aNovartis Foundation symposium ;$vv. 292
300   $aDescription based upon print version of record.
311   $a0-470-72325-4 
320   $aIncludes bibliographical references and index.
327   $aDefining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
327   $aCD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index
330   $aThis book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.The book integrates information from human and animal studies.The book considers T1D within the broader context of autoimmune disease.The format contains several discussions, which address specific questions and provides
410  0$aNovartis Foundation symposium ;$vv. 292.
606   $aDiabetes$xImmunotherapy$vCongresses
606   $aDiabetes$xTreatment$vCongresses
608   $aElectronic books.
615  0$aDiabetes$xImmunotherapy
615  0$aDiabetes$xTreatment
676   $a616.46206
712 02$aNovartis Foundation.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910144093303321
996   $aDefining optimal immunotherapies for type 1 diabetes$92186506
997   $aUNINA